Migraine and Headache
Researchers found evidence for a divergent association between lifetime MDD and the prevalence and severity of symptoms in patients with migraine.
Researchers suggest that improvement in cognitive function should be a goal for major depressive disorder because their data showed little improvement in the cognitive abilities of patients with major depression after treatment with psychological interventions.
The treatment is currently being evaluated in a Phase 2 study (ELEVATE) in patients with major depressive disorder who have had an inadequate response to standard antidepressant therapy.
Multimarker inflammatory biosignatures are expected to facilitate diagnosis and predict treatment outcomes for various central nervous system disorders, particularly Alzheimer disease and major depressive disorder.
The Food and Drug Administration (FDA) has granted Fast Track designation to an investigational intranasal formulation of racemic ketamine for the potential treatment of acute suicidal ideation and behavior in patients with major depressive disorder.
Effectively treating pain may help improve cognitive and functional outcomes in patients with depression.
There was insufficient evidence to recommend screening in children aged 11 and younger.
Sixty percent of patients responded to treatment.
Delay or lack of speech, seizures, and walking/balance disorders are some of the symptoms associated with AS.
Those with increased connectivity had lower BDI scores following treatment and over time.